Brokers Set Expectations for Palisade Bio Q3 Earnings

Palisade Bio, Inc. (NASDAQ:PALI) – Equities researchers at Brookline Capital Markets issued their Q3 2026 EPS estimates for Palisade Bio in a report released on Wednesday, April 15th. Brookline Capital Markets analyst K. Raja anticipates that the company will post earnings of ($0.06) per share for the quarter. The consensus estimate for Palisade Bio’s current full-year earnings is ($0.21) per share. Brookline Capital Markets also issued estimates for Palisade Bio’s Q4 2026 earnings at ($0.06) EPS.

Several other research analysts have also recently weighed in on PALI. Piper Sandler assumed coverage on shares of Palisade Bio in a research report on Monday, December 29th. They issued an “overweight” rating and a $25.00 price objective for the company. Wall Street Zen upgraded shares of Palisade Bio from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. B. Riley Financial started coverage on shares of Palisade Bio in a research report on Friday, January 9th. They issued a “buy” rating and a $7.00 price objective for the company. HC Wainwright started coverage on shares of Palisade Bio in a research report on Thursday, March 26th. They set a “buy” rating and a $7.00 target price for the company. Finally, Stifel Nicolaus started coverage on shares of Palisade Bio in a research report on Wednesday, February 25th. They set a “buy” rating and a $5.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Palisade Bio currently has a consensus rating of “Moderate Buy” and an average price target of $10.20.

Palisade Bio Trading Up 12.0%

NASDAQ:PALI opened at $2.80 on Monday. The firm has a 50 day moving average of $1.91 and a 200-day moving average of $1.91. Palisade Bio has a 1 year low of $0.53 and a 1 year high of $2.80. The stock has a market capitalization of $464.46 million, a P/E ratio of -1.32 and a beta of 1.36.

Hedge Funds Weigh In On Palisade Bio

Several institutional investors and hedge funds have recently made changes to their positions in PALI. Total Clarity Wealth Management Inc. acquired a new position in shares of Palisade Bio in the 4th quarter valued at $70,000. Jefferies Financial Group Inc. acquired a new position in shares of Palisade Bio in the 4th quarter valued at $110,000. Geode Capital Management LLC grew its holdings in shares of Palisade Bio by 5,780.7% in the 4th quarter. Geode Capital Management LLC now owns 1,565,452 shares of the company’s stock valued at $3,681,000 after buying an additional 1,538,832 shares during the period. Goldman Sachs Group Inc. acquired a new position in shares of Palisade Bio in the 4th quarter valued at $1,310,000. Finally, TD Asset Management Inc acquired a new position in Palisade Bio in the 4th quarter worth $480,000. Institutional investors and hedge funds own 11.79% of the company’s stock.

About Palisade Bio

Palisade Bio, Inc is a clinical?stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll?like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.